2023 World Conference on Lung Cancer (Posters)-EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis

EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis - PDF(Abstract)

Back to course

Pdf Summary

This study conducted a network meta-analysis to compare the efficacy of nivolumab plus ipilimumab (NIVO IPI) with other immunotherapy-based regimens in patients with first-line metastatic non-small cell lung cancer (mNSCLC) and tumor programmed death ligand 1 (PD-L1) 1%. The aim was to quantify the long-term comparative efficacy in this population with a large unmet need. <br /><br />A systematic literature review was conducted to identify phase 3 randomized controlled trials (RCTs) with 3 years of follow-up, evaluating immunotherapy-based regimens approved for first-line mNSCLC. RCTs that reported overall survival (OS) and/or progression-free survival (PFS) within the PD-L1 1% population were included. The target populations were further defined by histology.<br /><br />The results showed that NIVO IPI had lower hazard ratios (HRs) for OS and PFS compared to other IO-based regimens over time in both the non-squamous and squamous target populations. The HRs at 5 years of NIVO IPI versus comparators were favorable, with statistically significant improvements over atezolizumab bevacizumab chemotherapy in the non-squamous setting, and over pembrolizumab chemotherapy in the squamous setting.<br /><br />Overall, this study suggests a trend towards long-term survival benefit with NIVO IPI compared to other IO-based combinations among patients with PD-L1 1%. These findings highlight the potential efficacy of NIVO IPI as a first-line treatment option for patients with metastatic NSCLC.

Asset Subtitle

Adam Lee

Meta Tag

Speaker Adam Lee

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

network meta-analysis

nivolumab plus ipilimumab

immunotherapy-based regimens

metastatic non-small cell lung cancer

tumor programmed death ligand 1

systematic literature review

phase 3 randomized controlled trials

overall survival

progression-free survival

histology